SLC5A2 and hydrops fetalis: Bothcomponents of the primary outcome had consistent reductions with SGLT2 inhibitoruse, with demonstrated reductions in cardiovascular death, first HFhospitalization and worsening HF events when each outcome was consideredseparately.